目的 探討正清風(fēng)痛寧緩釋片聯(lián)合普瑞巴林治療帶狀皰疹后遺神經(jīng)痛的臨床效果。方法 選取2019年1月—2020年12月河南科技大學(xué)第一附屬醫(yī)院收治的130例帶狀皰疹后遺神經(jīng)痛患者，按隨機(jī)數(shù)字表法分成對(duì)照組和治療組，每組各65例。對(duì)照組口服普瑞巴林膠囊，起始劑量75 mg/次，2次/d，連用1周后增至150 mg/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服正清風(fēng)痛寧緩釋片，2片/次，2次/d。連續(xù)治療4周后評(píng)價(jià)兩組療效。比較治療前后兩組疼痛視覺(jué)模擬量表（VAS）評(píng)分、失眠嚴(yán)重程度指數(shù)（ISI）總分、36項(xiàng)健康調(diào)查簡(jiǎn)表（SF-36）總分及血清白細(xì)胞介素（IL）-17、C反應(yīng)蛋白（CRP）、前列腺素E₂（PGE₂）水平。結(jié)果 治療后，治療組總有效率為95.4%，顯著高于對(duì)照組的84.6%（P＜0.05）。治療后，治療組止痛起效時(shí)間和疼痛緩解時(shí)間均較對(duì)照組顯著縮短（P＜0.05）。治療后，兩組疼痛VAS評(píng)分、ISI總分均顯著低于治療前，SF-36總分均顯著高于治療前（P＜0.05）；且治療后，治療組疼痛VAS評(píng)分、ISI總分和SF-36總分改善均顯著優(yōu)于對(duì)照組（P＜0.05）。治療后，兩組血清IL-17、CRP和PGE₂水平均顯著下降（P＜0.05）；且治療后，治療組血清IL-17、CRP和PGE₂水平均顯著低于對(duì)照組（P＜0.05）。結(jié)論 正清風(fēng)痛寧緩釋片聯(lián)合普瑞巴林對(duì)帶狀皰疹后遺神經(jīng)痛患者具有確切的臨床療效，能安全有效地緩解患者疼痛、改善睡眠與生活質(zhì)量，并可進(jìn)一步抑制血清IL-17、CRP和PGE₂水平。

Objective To investigate the clinical effect of Zhengqing Fengtongning Sustained-release Tablet combined with pregabalin in treatment of postherpetic neuralgia.Methods A total of 130 patients with postherpetic neuralgia who were admitted to The First Affiliated Hospital of Henan University of Science and Technology from January 2019 to December 2020 were selected and divided into control group (n =65) and treatment group (n=65) according to the random number table method.Patients in the control group were po administered with Pregabalin Capsule,the initial dose was 75 mg/time,twice daily,and then increased to 150 mg/time,twice daily after continuous use for 1 week.Patients in the treatment group were po administered with Zhengqing Fengtongning Sustained-release Tablet on the basis of the control group,2 tablet/time,twice daily.The analgesic efficacy of the two groups was evaluated after 4 weeks of continuous treatment.The pain visual analog scale (VAS) score,insomnia severity index (ISI) total score,36-item short form of health survey (SF-36) total score,serum interleukin (IL)-17,C-reactive protein (CRP),prostaglandin E₂(PGE₂) levels were compared between the two groups before and after treatment.Results After treatment,the total effective rate of the treatment group was 95.4%,which was significantly higher than 84.6% of the control group (P<0.05).After treatment,the analgesic onset time and pain relief time in the treatment group were significantly shorter than those in the control group (P<0.05).After treatment,the VAS score and ISI total score of pain in the two groups were significantly lower than before treatment,but the SF-36 total score was significantly higher than before treatment (P<0.05).After treatment,the VAS score,ISI total score,and SF-36 total score of the treatment group were significantly improved than those of the control group (P<0.05).After treatment,the serum levels of IL-17,CRP,and PGE₂ in the two groups were significantly decreased (P<0.05).After treatment,the levels of serum IL-17,CRP,and PGE₂ in the treatment group were significantly lower than those in the control group (P<0.05).Conclusion Zhengqing Fengtongning Sustained-release Tablet combined with pregabalin has definite clinical effect in treatment of postherpetic neuralgia,and can safely and effectively relieve pain,improve sleep and life quality,which can inhibit the levels of serum IL-17,CRP,and PGE₂.

R971

河南科技大學(xué)青年科學(xué)基金資助項(xiàng)目(2020QN035)